Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials
The U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-to-use 50mg/10 ml single use vial presentation.

Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-to-use 50mg/10 ml single use vial presentation. Under an exclusive licensing agreement with Endo International’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, Par Pharmaceuticals’ Sterile Products division will launch and distribute the product. This is the first approval under the previously announced collaboration between Nevakar and Endo for the development of five differentiated, sterile injectable products in the U.S. and Canada. Under the terms of the agreement, Nevakar has responsibility to develop and obtain FDA approval for these products and Par Pharmaceuticals’ Sterile Products division will launch and distribute the products.

“We are pleased to have received approval for this convenient, patent pending, ready-to-use form of a frequently used treatment for clinically important hypotension during anesthesia. We value our strong partnership with Endo, a respected pharmaceutical company with a significant and growing presence in sterile and critical care products as we pursue our mission to develop innovative pharmaceutical products that improve patient care and quality of life,” stated Navneet Puri, Ph.D., Founder, Chairman and Chief Executive Officer of Nevakar.

About Nevakar Inc.
Nevakar Inc. is growing as a fully integrated biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Founded in 2015, and headquartered in Bridgewater New Jersey, the Company is focused on developing and commercializing innovative products to address unmet medical needs, thereby improving patient care and quality of life. Nevakar utilizes the 505(b)(2) regulatory pathway, along with its proven expertise in the development of novel and proprietary sterile pharmaceutical products to identify, develop, and obtain regulatory approval for its products. Additional information is available at www.nevakar.com.

Tags : #NEVAKAR #FDA #EPHEDRINESULPHATEINJECTION #NASDAQ #INJECTIONS

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

University of Birmingham Dubai invites applications for MSc in Financial Data ScienceJuly 08, 2025
Benefits of ShirodharaJuly 07, 2025
WIKA India Launches “Re-Inventing Hygiene” Campaign to Advance Standards in Food & Pharma InstrumentationJuly 07, 2025
Cambodia is 2nd Asian country to rollout long-acting injectable HIV prevention optionJuly 07, 2025
Wheels of Care: How Tele-MRVs Are Reaching Mothers Left BehindJuly 07, 2025
Personalized Psychiatry's Developing Use of PharmacogenomicsJuly 07, 2025
Honourable Ministers Shri Anil Kumar Bachoo and Shri Palanivel Thiaga Rajan Open IIRSI 2025 Convention on Intraocular Implant & Refractive SurgeryJuly 05, 2025
A 69-year-old retired teacher gives a lesson of life by donating multiple organsJuly 05, 2025
Silent Scans, Smarter Eyes: Inside India’s First AI Teleradiology HubsJuly 05, 2025
Can You Hear Me Now? The Quiet Revolution of Tele-Audiology in Rural Childhood CareJuly 05, 2025
What’s on Their Plate? Uncovering Malnutrition Through Midday Meal DataJuly 05, 2025
Can Diabetics Conquer Space? The Mission That’s Changing Medicine on Earth and BeyondJuly 05, 2025
Center for Diagnostics and Telemedicine Celebrates Graduation of First Masters in Medical Artificial IntelligenceJuly 04, 2025
Sightsavers India Fellowship Programme Invites Applications for 2025July 04, 2025
After 4 Surgeries & 15kg Abdominal Tumour, 61-YO Reclaims Life In Marathon Operation At HCGMCCJuly 04, 2025
The DNA Warning: Are Genomic Screening Camps the Early Alarm We Need?July 04, 2025
Ticked, Tapped, and Forgotten? The Truth About Digital Consent FormsJuly 04, 2025
Evaluating the Impact of AI Chatbots in Mental Health Support for College StudentsJuly 04, 2025
Integrating Oral Health with Primary Care: Pilot Programs in Rural MaharashtraJuly 04, 2025
Will governments firewall public health from tobacco industry's lies and deceptive tactics?July 03, 2025